6CM
KYTX icon

683 Capital Management’s Kyverna Therapeutics KYTX Stock Holding History

683 Capital Management’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$734K Sell
85,000
-29,900
-26% -$249K 0.04% 157
2025
Q4 		$1.08M Buy
+114,900
New +$853K 0.05% 132

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

683 Capital Management's KYTX Position: Q1 2026 in Review

683 Capital Management reduced its Kyverna Therapeutics (KYTX) stake by 26% in Q1 2026, selling an estimated $249K and leaving 85,000 shares worth $734K. The position accounts for 0.04% of the portfolio, ranked #157.

683 Capital Management first reported a position in KYTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.08M in Q4 2025. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • 683 Capital Management held 85,000 shares of Kyverna Therapeutics worth $734K as of Q1 2026.
  • 683 Capital Management sold 29,900 Kyverna Therapeutics shares in Q1 2026, an estimated $249K.
  • Kyverna Therapeutics made up 0.04% of 683 Capital Management's portfolio in Q1 2026, its #157 holding.
  • 683 Capital Management first reported a position in Kyverna Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 683 Capital Management's Kyverna Therapeutics position peaked at $1.08M in Q4 2025.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.